American Century Companies Inc. lessened its holdings in shares of Mylan N.V. (NASDAQ:MYL) by 18.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,486 shares of the company’s stock after selling 2,359 shares during the quarter. American Century Companies Inc.’s holdings in Mylan were worth $329,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Meeder Asset Management Inc. raised its stake in Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after purchasing an additional 1,475 shares during the period. BT Investment Management Ltd bought a new stake in Mylan during the 3rd quarter valued at approximately $142,000. Global X Management Co. LLC raised its stake in Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after purchasing an additional 1,786 shares during the period. Doliver Capital Advisors LP bought a new stake in Mylan during the 2nd quarter valued at approximately $201,000. Finally, Eagle Global Advisors LLC bought a new stake in Mylan during the 2nd quarter valued at approximately $205,000. 73.86% of the stock is currently owned by institutional investors.

Several analysts recently issued reports on MYL shares. Mizuho reissued a “buy” rating and set a $37.00 target price (down previously from $53.00) on shares of Mylan in a research note on Sunday, August 20th. Citigroup raised Mylan from a “neutral” rating to a “buy” rating and lifted their target price for the company from $36.00 to $42.00 in a research note on Wednesday, August 16th. UBS reissued a “buy” rating and set a $46.00 target price (down previously from $50.00) on shares of Mylan in a research note on Thursday, August 10th. BMO Capital Markets reissued a “buy” rating and set a $45.00 target price on shares of Mylan in a research note on Friday, September 29th. Finally, ValuEngine raised Mylan from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. Mylan presently has a consensus rating of “Buy” and an average target price of $41.49.

Mylan N.V. (MYL) opened at $38.12 on Friday. The firm has a market capitalization of $19,596.02, a P/E ratio of 7.77, a PEG ratio of 2.00 and a beta of 1.39. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.

Mylan (NASDAQ:MYL) last released its earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.38 EPS. analysts forecast that Mylan N.V. will post 4.56 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/02/mylan-n-v-myl-position-cut-by-american-century-companies-inc.html.

Mylan Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.